← All trials
NCT04849364
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 24, 2021
- Primary completion
- Jan 31, 2024
- Completion date
- Jan 31, 2029
- First posted
- Apr 19, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 197
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Indiana UniversityLead sponsor
- PfizerCollaborator
- Hoosier Cancer Research NetworkSponsor investigator
- GenentechCollaborator
- Indiana UniversityOverall official - principal investigator
- Indiana UniversityCollaborator
- Foundation MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.